Synapse - Works

Results (5608)

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Meeting Abstract

Hecht, J. R.; Naing, A.; Falchook, G. S.; Patel, M. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Javle, M.; Bendell, J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Meeting Abstract

de Bono, J. S.; Hansen, A.; Choudhury, A. D.; Cook, N.; Heath, E. I.; Higano, C.; Linch, M.; Martin-Liberal, J.; Rathkopf, D. E.; Wisinski, K. B.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

Meeting Abstract

Boni, V.; Garcia-Corbacho, J.; Ott, P. A.; Cho, D. C.; Autio, K. A.; Uboha, N.; Spira, A. I.; Humphrey, R.; Will, M.; Naing, A.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Meeting Abstract

Choueiri, T. K.; Flaifel, A.; Xie, W.; Braun, D.; Ficial, M.; Jennings, R.; Nassar, A.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

Meeting Abstract

Autio, K. A.; Naing, A.; Hung, A.; Oft, M.; Leveque, J.; Falchook, G. S.
Annals of Oncology (2018)

Fulltext@MSK | Save

Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial

Meeting Abstract

Lyman, S. K.; Gordon, J.; DuPage, A.; Pramanik, P.; Howng, B.; Winter, M. B.; Popova, I. K.; Vasiljeva, O.; Jones, J.; Wong, K.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Comparative genomic profiling of matched primary and metastatic tumors in renal cell carcinoma

Journal Article

Becerra, M. F.; Reznik, E.; Redzematovic, A.; Tennenbaum, D. M.; Kashan, M.; Ghanaat, M.; Casuscelli, J.; Manley, B.; Jonsson, P.; DiNatale, R. G.; more...
European Urology Focus (2018)

Fulltext@MSK | Save

Robot-assisted versus open radical cystectomy in patients receiving perioperative chemotherapy for muscle-invasive bladder cancer: The oncologist's perspective from a multicentre study

Journal Article

Necchi, A.; Pond, G. R.; Smaldone, M. C.; Pal, S. K.; Chan, K.; Wong, Y. N.; Viterbo, R.; Sonpavde, G.; Harshman, L. C.; Crabb, S.; more...
European Urology Focus (2018)

Fulltext@MSK | Save

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Journal Article

Leiserson, M. D. M.; Syrgkanis, V.; Gilson, A.; Dudik, M.; Gillett, S.; Chayes, J.; Borgs, C.; Bajorin, D. F.; Rosenberg, J. E.; Funt, S.; more...
PLoS ONE (2018)

Fulltext@MSK | Save

Genomically annotated risk model for advanced renal-cell carcinoma: A retrospective cohort study

Journal Article

Voss, M. H.; Reising, A.; Cheng, Y.; Patel, P.; Marker, M.; Kuo, F.; Chan, T. A.; Choueiri, T. K.; Hsieh, J. J.; Hakimi, A. A.; more...
Lancet Oncology (2018)

Fulltext@MSK | Save